Product
Dendritic cell + Cytokine-induced killer cell immunotherapy
1 clinical trial
2 indications
Indication
Pancreatic Ductal AdenocarcinomaIndication
Advanced Solid TumorClinical trial
Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma PatientsStatus: Recruiting, Estimated PCD: 2024-12-01